Company intelligence / Profile preview

Zanos

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Zanos is a biotechnology company pioneering the development of therapeutics that target Z-nucleic acids (Z-DNA and Z-RNA) and their associated binding proteins. The company focuses on the ZBP1 and ADAR1 pathways, which play critical roles in innate immunity, cell death (necroptosis), and inflammation. By modulating these pathways, Zanos aims to treat a variety of cancers and inflammatory disorders where Z-nucleic acid signaling is dysregulated. The company's approach leverages deep expertise in the structural biology of alternative DNA/RNA conformations to unlock new classes of precision medicines.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Zanos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zanos.

Explore the full profile